[1. Casanova JL, Abel L. The genetic theory of infectious diseases: A brief history and selected illustrations. Annu Rev Genomics Hum Genet. 2013;14:215-43. DOI: 10.1146/annurev-genom-091212-15344810.1146/annurev-genom-091212-153448498076123724903]Search in Google Scholar
[2. Pandolfi F, Milito C, Conti V, Pagliari D, Frosali S, Cianci R, et al. Common variable immunodeficiency - New insight into the pathogenesis and the quest for a workable classification. J Biol Regul Homeost Agents. 2013;27(2):285-9.]Search in Google Scholar
[3. Maggina P, Gennery AR. Classification of primary immunodeficiencies: need for a revised approach? J Allergy Clin Immunol. 2013 Feb;131(2):292-4. DOI: 10.1016/j.jaci.2012.10.00810.1016/j.jaci.2012.10.00823174660]Search in Google Scholar
[4. Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: An update on the classification from the International Union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5(APR). DOI: 10.3389/ fimmu.2014.0016210.3389/fimmu.2014.00460]Search in Google Scholar
[5. Chinen J, Notarangelo LD, Shearer WT. Advances in basic and clinical immunology in 2013. J Allergy Clin Immunol. 2014 Feb 28;133(4):967-76. DOI: 10.1016/j. jaci.2014.01.026]Search in Google Scholar
[6. Hernandez-Trujillo V. New genetic discoveries and primary immune deficiencies. Clin Rev Allergy Immunol. 2014;46(2):145-53. DOI: 10.1007/s12016-013-8380-010.1007/s12016-013-8380-023860595]Search in Google Scholar
[7. Gathmann B, Binder N, Ehl S, Kindle G. The European internet-based patient and research database for primary immunodeficiencies: Update 2011. Clin Exp Immunol. 2012;167(3):479-91. DOI: 10.1111/j.1365-2249.2011.04542.x10.1111/j.1365-2249.2011.04542.x337428022288591]Search in Google Scholar
[8. Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013 Jan;33(1):1-7. DOI: 10.1007/s10875-012-9751-710.1007/s10875-012-9751-722847546]Search in Google Scholar
[9. Chapel H, Lucas M, Lee M, Björkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008 Jul 15;112(2):277-86. DOI: 10.1182/blood-2007-11-12454510.1182/blood-2007-11-12454518319398]Search in Google Scholar
[10. Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008 Jan 1;111(1):77-85. DOI: 10.1182/blood-2007-06-09174410.1182/blood-2007-06-09174417898316]Search in Google Scholar
[11. Baldovino S, Montin D, Martino S, Sciascia S, Menegatti E, Roccatello D. Common variable immunodeficiency: crossroads between infections, inflammation and autoimmunity. Autoimmun Rev. 2013 Jun;12(8):796-801. DOI: 10.1016/j.autrev.2012.11.00310.1016/j.autrev.2012.11.00323219764]Search in Google Scholar
[12. Gathmann B, Mahlaoui N, Gerard L, Oksenhendler E, Warnatz K, Schulze I, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014 Feb 27;Epub ahead of print. DOI: 10.1016/j.jaci.2013.12.107710.1016/j.jaci.2013.12.107724582312]Search in Google Scholar
[13. Eibel H, Salzer U, Warnatz K. Common variable immunodeficiency at the end of a prospering decade: Towards novel gene defects and beyond. Curr Opin Allergy Clin Immunol. 2010;10(6):526-33. DOI: 10.1097/ ACI.0b013e32833fea1c10.1097/ACI.0b013e32833fea1c]Search in Google Scholar
[14. Keller MD, Jyonouchi S. Chipping away at a mountain: Genomic studies in common variable immunodeficiency. Autoimmun Rev. 2013;12(6):687-9. DOI: 10.1016/j.autrev.2012.10.01710.1016/j.autrev.2012.10.017]Search in Google Scholar
[15. Todoric K, Koontz JB, Mattox D, Tarrant TK. Autoimmunity in immunodeficiency. Curr Allergy Asthma Rep. 2013;13(4):361-70. DOI: 10.1007/s11882-013-0350-310.1007/s11882-013-0350-3]Search in Google Scholar
[16. Bousfiha AA, Jeddane L, Ailal F, Al HW, Conley ME, Cunningham-Rundles C, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol. 2013 Aug;33(6):1078-87. DOI: 10.1007/s10875-013-9901-610.1007/s10875-013-9901-6]Search in Google Scholar
[17. Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011 Oct;51(1):61-70. DOI: 10.1007/s12026-011-8241-y10.1007/s12026-011-8241-y]Search in Google Scholar
[18. Routes J, Abinun M, Al-Herz W, Bustamante J, Condino- Neto A, de la Morena MT, et al. ICON: The early diagnosis of congenital immunodeficiencies. J Clin Immunol. 2014 May;34(4):398-424. DOI: 10.1007/ s10875-014-0003-x10.1007/s10875-014-0003-x]Search in Google Scholar
[19. Modell F, Puente D, Modell V. From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of Primary Immunodeficiencies. Immunol Res. 2009;44(1-3):132-49. DOI: 10.1007/s12026-008-8092-310.1007/s12026-008-8092-3]Search in Google Scholar
[20. Borte S, Borte M. Decreasing time-to-diagnosis in primary antibody deficiencies - The case for newborn screening programmes and awareness campaigns. Eur Infect Dis. 2012;6(2):99-104.]Search in Google Scholar
[21. MacGinnitie A, Aloi F, Mishra S. Clinical characteristics of pediatric patients evaluated for primary immunodeficiency. Pediatr Allergy Immunol. 2011;22(7):671-5. DOI: 10.1111/j.1399-3038.2011.01167.x10.1111/j.1399-3038.2011.01167.x]Search in Google Scholar
[22. Motamed F, Aghamohammadi A, Soltani M, Mansouri M, Rezaei N, Teimourian S, et al. Evaluation of liver diseases in Iranian patients with primary antibody deficiencies. Ann Hepatol. 2009 Jul;8(3):196-202.10.1016/S1665-2681(19)31765-X]Search in Google Scholar
[23. Dehkordy SF, Aghamohammadi A, Ochs HD, Rezaei N. Primary immunodeficiency diseases associated with neurologic manifestations. J Clin Immunol. 2012;32(1):1-24. DOI: 10.1007/s10875-011-9593-810.1007/s10875-011-9593-822038677]Search in Google Scholar
[24. Agarwal S, Mayer L. Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol. 2013;11(9):1050-63. DOI: 10.1016/j.cgh.2013.02.02410.1016/j.cgh.2013.02.024380020423501398]Search in Google Scholar
[25. Hosseinverdi S, Hashemi H, Aghamohammadi A, Ochs HD, Rezaei N. Ocular involvement in primary immunodeficiency diseases. J Clin Immunol. 2014;34(1):23-38. DOI: 10.1007/s10875-013-9974-210.1007/s10875-013-9974-224292697]Search in Google Scholar
[26. Lehman H. Skin manifestations of primary immune deficiency. Clin Rev Allergy Immunol. 2014;46(2):112-9. DOI: 10.1007/s12016-013-8377-810.1007/s12016-013-8377-823760761]Search in Google Scholar
[27. Wood P. Primary antibody deficiencies: Recognition, clinical diagnosis and referral of patients. Clin Med (Lond Engl). 2009;9(6):595-9. DOI: 10.7861/clinmedicine. 9-6-595]Search in Google Scholar
[28. Abraham RS. Relevance of laboratory testing for the diagnosis of primary immunodeficiencies: A review of case-based examples of selected immunodeficiencies. Clin Mol Allergy. 2011;9:6. DOI: 10.1186/1476-7961-9-610.1186/1476-7961-9-6308080721477322]Search in Google Scholar
[29. de Vries E, European Society for Immunodeficiencies (ESID) members. Patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol. 2012 Jan;167(1):108-19. DOI: 10.1111/j.1365-2249.2011.04461.x10.1111/j.1365-2249.2011.04461.x324809222132890]Search in Google Scholar
[30. Locke BA, Dasu T, Verbsky JW. Laboratory diagnosis of primary immunodeficiencies. Clin Rev Allergy Immunol. 2014 Apr;46(2):154-68. DOI: 10.1007/s12016-014-8412-410.1007/s12016-014-8412-424569953]Search in Google Scholar
[31. Borte S, Von Dobeln U, Hammarström L. Guidelines for newborn screening of primary immunodeficiency diseases. Curr Opin Hematol. 2013;20(1):48-54. DOI: 10.1097/MOH.0b013e32835a913010.1097/MOH.0b013e32835a913023108220]Search in Google Scholar
[32. Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133(4):1092-8. DOI: 10.1016/j.jaci.2013.09.04410.1016/j.jaci.2013.09.044397226624290292]Search in Google Scholar
[33. Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2005 Feb;115(2):391-8. DOI: 10.1016/j.jaci.2004.10.01210.1016/j.jaci.2004.10.01215696101]Search in Google Scholar
[34. Janik DK, Lindau-Shepard B, Comeau AM, Pass KA. A multiplex immunoassay using the Guthrie specimen to detect T-cell deficiencies including severe combined immunodeficiency disease. Clin Chem. 2010 Sep;56(9):1460-5. DOI: 10.1373/ clinchem.2010.14432910.1373/clinchem.2010.144329322018320660143]Search in Google Scholar
[35. Borte S, Von Döbeln U, Fasth A, Wang N, Janzi M, Winiarski J, et al. Neonatal screening for severe prima ry immunodeficiency diseases using high-throughput triplex real-time PCR. Blood. 2012;119(11):2552-5. DOI: 10.1182/blood-2011-08-37102110.1182/blood-2011-08-37102122130802]Search in Google Scholar
[36. Chiarini M, Zanotti C, Serana F, Sottini A, Bertoli D, Caimi L, et al. T-cell receptor and K-deleting recombination excision circles in newborn screening of Tand B-cell defects: Review of the literature and future challenges. J Public Health Res. 2013;2(1):9-16. DOI: 10.4081/jphr.2013.e310.4081/jphr.2013.e3414032225170474]Search in Google Scholar
[37. Serana F, Chiarini M, Zanotti C, Sottini A, Bertoli D, Bosio A, et al. Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies. J Transl Med. 2013;11:119. DOI: 10.1186/1479-5876-11-11910.1186/1479-5876-11-119366688923656963]Search in Google Scholar
[38. la Marca G. Mass spectrometry in clinical chemistry: the case of newborn screening. J Pharm Biomed Anal. 2014 Apr 28;E pub ahead of print. DOI: 10.1016/j. jpba.2014.03.047]Search in Google Scholar
[39. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174(2):203-11. DOI: 10.1111/cei.1217810.1111/cei.12178382882323859429]Search in Google Scholar
[40. Seppänen M, Aghamohammadi A, Rezaei N. Is there a need to redefine the diagnostic criteria for common variable immunodeficiency? Expert Rev Clin Immunol. 2014;10(1):1-5. DOI: 10.1586/1744666X.2014.87047810.1586/1744666X.2014.87047824325452]Search in Google Scholar
[41. Nijman IJ, Van Montfrans JM, Hoogstraat M, Boes ML, Van De Corp, Renner ED, et al. Targeted next-generation sequencing: A novel diagnostic tool for primary immunodeficiencies. J Allergy Clin Immunol. 2014;133(2):529-34. DOI: 10.1016/j.jaci.2013.08.03210.1016/j.jaci.2013.08.03224139496]Search in Google Scholar
[42. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76. DOI: 10.1016/j.cell.2006.07.02410.1016/j.cell.2006.07.02416904174]Search in Google Scholar
[43. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007 Nov 30;131(5):861-72. DOI: 10.1016/j. cell.2007.11.019]Search in Google Scholar
[44. Pessach IM, Ordovas-Montanes J, Zhang SY, Casanova JL, Giliani S, Gennery AR, et al. Induced pluripotent stem cells: A novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol. 2011;127(6):1400-7. DOI: 10.1016/j.jaci.2010.11.00810.1016/j.jaci.2010.11.008308199321185069]Search in Google Scholar
[45. Hernandez-Trujillo HS, Chapel H, Lo RI, V, Notarangelo LD, Gathmann B, Grimbacher B, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012 Jul;169(1):57-69. DOI: 10.1111/j.1365-2249.2012.04588.x10.1111/j.1365-2249.2012.04588.x339047422670779]Search in Google Scholar
[46. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006 Apr;117(4 Suppl): S525-S553. DOI: 10.1016/j.jaci.2006.01.01510.1016/j.jaci.2006.01.01516580469]Search in Google Scholar
[47. Stonebraker JS, Farrugia A, Gathmann B, ESID Registry Woking Party, Orange JS. Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin. J Clin Immunol. 2014 Feb;34(2):233-44. DOI: 10.1007/s10875-013-9975-110.1007/s10875-013-9975-124338563]Search in Google Scholar
[48. Robinson P, Anderson D, Brouwers M, Feasby TE, Hume H. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev. 2007 Apr;21(2 Suppl 1):S3-S8. DOI: 10.1016/j.tmrv.2007.01.00410.1016/j.tmrv.2007.01.00417397767]Search in Google Scholar
[49. Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010 Jan;24(Suppl. 1):S28-S50. DOI: 10.1016/j. tmrv.2009.09.011]Search in Google Scholar
[50. Sewell WC, Kerr J, Behr-Gross ME, Peter HH. European consensus proposal for immunoglobulin therapies. Eur J Immunol. 2014 Jun 28. DOI: 10.1002/ eji.201444700]Search in Google Scholar
[51. Beauté J, Levy P, Millet V, Debré M, Dudoit Y, Le Mignot L, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160(2):240-5. DOI: 10.1111/j.1365-2249.2009.04079.x10.1111/j.1365-2249.2009.04079.x285794720041884]Search in Google Scholar
[52. Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: An evidence-based review. Drugs. 2013;73(12):1307-19. DOI: 10.1007/s40265-013-0094-310.1007/s40265-013-0094-323861187]Search in Google Scholar
[53. Torgerson TR, Bonagura VR, Shapiro RS. Clinical ambiguities - Ongoing questions. J Clin Immunol. 2013;33(2 SUPPL.):S99-S103. DOI: 10.1007/s10875-012-9851-410.1007/s10875-012-9851-423242829]Search in Google Scholar
[54. Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23(1):55-60. DOI: 10.1111/j.1365-3148.2012.01201.x10.1111/j.1365-3148.2012.01201.x358087923167310]Search in Google Scholar
[55. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010 Mar;30(2):301-7. DOI: 10.1007/s10875-009-9352-210.1007/s10875-009-9352-220082124]Search in Google Scholar
[56. Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-fa cilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951-7. DOI: 10.1016/j. jaci.2012.06.021]Search in Google Scholar
[57. Chapel H, Gardulf A. Subcutaneous immunoglobulin replacement therapy: The European experience. Curr Opin Allergy Clin Immunol. 2013;13(6):623-9. DOI: 10.1097/ACI.000000000000001310.1097/ACI.000000000000001324126615]Search in Google Scholar
[58. Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: Quality of life and views on treatment. Patient Preference Adherence. 2014;8:621-9. DOI: 10.2147/PPA.S6077110.2147/PPA.S60771401437724833896]Search in Google Scholar
[59. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010 Oct;137(1):21-30. DOI: 10.1016/j.clim.2010.06.01210.1016/j.clim.2010.06.01220675197]Search in Google Scholar
[60. Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012 Aug;169(2):172-81. DOI: 10.1111/j.1365-2249.2012.04594.x10.1111/j.1365-2249.2012.04594.x340637722774992]Search in Google Scholar
[61. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46(10):1547-54. DOI: 10.1086/58766910.1086/58766918419489]Search in Google Scholar
[62. Llobet MP, Soler-Palacin P, Detkova D, Hernandez M, Caragol I, Espanol T. Common variable immunodeficiency: 20-yr experience at a single centre. Pediatr Allergy Immunol. 2009 Mar;20(2):113-8. DOI: 10.1111/j.1399-3038.2008.00744.x10.1111/j.1399-3038.2008.00744.x18798799]Search in Google Scholar
[63. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: Results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315-22. DOI: 10.1007/s10875-011-9511-010.1007/s10875-011-9511-021365217]Search in Google Scholar
[64. Gregersen S, Aaløkken TM, Mynarek G, Fevang B, Holm AM, Ueland T, et al. Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors. Annals of Allergy, Asthma and Immunology. 2010;104(6):503-10. DOI: 10.1016/j. anai.2010.04.015]Search in Google Scholar
[65. Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, et al. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: Correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol. 2013;171(2):186-94. DOI: 10.1111/ cei.1200210.1111/cei.12002357328923286945]Search in Google Scholar
[66. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008 Jul;122(1):210-2. DOI: 10.1016/j.jaci.2008.04.04410.1016/j.jaci.2008.04.04418602574]Search in Google Scholar
[67. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133-41. DOI: 10.1016/j.clim.2011.01.00610.1016/j.clim.2011.01.00621353644]Search in Google Scholar
[68. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32(6):1153-64. DOI: 10.1007/s10875-012-9740-x10.1007/s10875-012-9740-x22828788]Search in Google Scholar
[69. Mouillot G, Carmagnat M, Gérard L, Garnier JL, Fieschi C, Vince N, et al. B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol. 2010;30(5):746-55. DOI: 10.1007/s10875-010-9424-310.1007/s10875-010-9424-320437084]Search in Google Scholar
[70. Resnick ES, Moshier EL, Godbold JH, Cunningham- Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650-7. DOI: 10.1182/ blood-2011-09-37794510.1182/blood-2011-09-377945328634322180439]Search in Google Scholar
[71. Rapley P, Davidson PM. Enough of the problem: a review of time for health care transition solutions for young adults with a chronic illness. J Clin Nurs. 2010 Feb;19(3-4):313-23. DOI: 10.1111/j.1365-2702.2009.03027.x10.1111/j.1365-2702.2009.03027.x20500270]Search in Google Scholar
[72. Agarwal S, Cunningham-Rundles C. Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement. J Allergy Clin Immunol. 2013;131(6):1699-701. DOI: 10.1016/j.jaci.2013.01.03610.1016/j.jaci.2013.01.036410231223518142]Search in Google Scholar
[73. O’Mahony B, Turner A. The Dublin Consensus Statement 2011 on vital issues relating to the collection and provision of blood components and plasma-derived medicinal products. Vox Sang. 2012 Feb;102(2):140-3. DOI: 10.1111/j.1423-0410.2011.01528.x10.1111/j.1423-0410.2011.01528.x21806632]Search in Google Scholar
[74. Späth PJ, Van Holten RW, Kempf C. Pathogen safety of immunoglobulin preparations. In: Wahn V, Orange J, editors. Clinical Use of Immunoglobulins. 2nd ed. Bremen - London - Boston: UNI-MED Verlag; 2013. p.26-50.]Search in Google Scholar
[75. Vassilev TL, Bineva IL, Dietrich G, Kaveri SV, Kazatchkine MD. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun. 1995 Jun;8(3):405-13. DOI: 10.1006/jaut.1995.003210.1006/jaut.1995.00327576001]Search in Google Scholar
[76. Späth PJ, Lutz HU. Naturally occurring antibodies/ autoantibodies in polyclonal immunoglobulin concentrates. Lutz HU, editor. Naturally Occurring Antibodies (NAbs). Advances in Experimental Medicine and Biology[ 750], 239-261. 16-4-2012. Austin, TX USA, Lan des Bioscience and Springer Science+Business Media. Advances in Experimental Medicine and Biology.10.1007/978-1-4614-3461-0_1822903679]Search in Google Scholar
[77. Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol. Pract. 2013;1(6):558-66. DOI: 10.1016/j.jaip.2013.09.01210.1016/j.jaip.2013.09.01224565701]Search in Google Scholar
[78. Gürcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev. 2010;9(8):553-9. DOI: 10.1016/j.autrev.2010.03.00310.1016/j.autrev.2010.03.00320346419]Search in Google Scholar
[79. Etscheid M, Breitner-Ruddock S, Gross S, Hunfeld A, Seitz R, Dodt J. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang. 2012 Jan;102(1):40-6. DOI: 10.1111/j.1423-0410.2011.01502.x10.1111/j.1423-0410.2011.01502.x21545600]Search in Google Scholar
[80. Desborough MJ, Miller J, Thorpe SJ, Murphy MF, Misbah SA. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Transfus Med. 2013 Oct 25;E-pub ahead of print. DOI: 10.1111/ tme.12083]Search in Google Scholar
[81. Schroeder HW, Jr., Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infect. 2012;40(6):601-11. DOI: 10.1007/s15010-012-0323-910.1007/s15010-012-0323-9350119122968971]Search in Google Scholar
[82. Dhainaut F, Guillaumat PO, Dib H, Perret G, Sauger A, De Coupade C, et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang. 2013;104(2):115-26. DOI: 10.1111/j.1423-0410.2012.01648.x10.1111/j.1423-0410.2012.01648.x358088023003576]Search in Google Scholar
[83. Medical Advisory Committee of the Immune Deficiency Foundation, Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014 Apr;133(4):961-6. DOI: 10.1016/j.jaci.2013.11.04310.1016/j.jaci.2013.11.043400934724582311]Search in Google Scholar
[84. Worth AJJ, Booth C, Veys P. Stem cell transplantation for primary immune deficiency. Curr Opin Hematol. 2013;20(6):501-8. DOI: 10.1097/MOH.0b013e-328365a13b]Search in Google Scholar
[85. Cavazzana-Calvo M, Andre-Schmutz I, Fischer A. Haematopoietic stem cell transplantation for SCID patients: Where do we stand? Br J Haematol. 2013;160(2):146-52. DOI: 10.1111/bjh.1211910.1111/bjh.12119]Search in Google Scholar
[86. Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014 Feb 1;383(9915):436-48. DOI: 10.1016/S0140-6736(13)62069-310.1016/S0140-6736(13)62069-3]Search in Google Scholar
[87. Lane JP, Evans PTG, Nademi Z, Barge D, Jackson A, Hambleton S, et al. Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies. Biol Blood Marrow Transplant. 2014;20(2):243-9. DOI: 10.1016/j. bbmt.2013.11.005]Search in Google Scholar
[88. Zou J, Sweeney CL, Chou BK, Choi U, Pan J, Wang H, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood. 2011 May 26;117(21):5561-72. DOI: 10.1182/blood-2010-12-32816110.1182/blood-2010-12-328161311002121411759]Search in Google Scholar
[89. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A. Gene therapy for primary immunodeficiencies: Part 1. Curr Opin Immunol 2012 Oct;24(5):580-4. DOI: 10.1016/j.coi.2012.08.00810.1016/j.coi.2012.08.00822981681]Search in Google Scholar
[90. Aiuti A, Bacchetta R, Seger R, Villa A, Cavazzana-Calvo M. Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol 2012 Oct;24(5):585-91. DOI: 10.1016/j.coi.2012.07.01210.1016/j.coi.2012.07.01222909900]Search in Google Scholar
[91. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy of primary T cell immunodeficiencies. Gene. 2013;525(2):170-3. DOI: 10.1016/j. gene.2013.03.092]Search in Google Scholar
[92. Touzot F, Hacein-Bey-Abina S, Fischer A, Cavazzana M. Gene therapy for inherited immunodeficiency. Expert Opin Biol Ther. 2014 Jun;14(6):789-98. DOI: 10.1517/14712598.2014.89581110.1517/14712598.2014.89581124823313]Search in Google Scholar
[93. Farinelli G, Capo V, Scaramuzza S, Aiuti A. Lentiviral vectors for the treatment of primary immunodeficiencies. J Inherit Metab Dis. 2014 Mar 12;Epub ahead of print. DOI: 10.1007/s10545-014-9690-y10.1007/s10545-014-9690-y24619149]Search in Google Scholar
[94. Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene. 2013 Aug 10;525(2):174-81. DOI: 10.1016/j.gene.2013.03.098 10.1016/j.gene.2013.03.098372541723566838]Search in Google Scholar